Emmanuel de la Mora Jimenez

A randomized controlled trial of CDK7 inhibitor samuraciclib plus fulvestrant in advanced HR+/HER2− breast cancer

Abstract Resistance to CDK4/6 inhibitors remains a major challenge in HR+/HER2− metastatic breast cancer. Samuraciclib is an oral selective CDK7 inhibitor that may overcome resistance to CDK4/6 inhibitors, targeting transcriptional programs sustaining tumor growth. This study pre...